AI copilot for doctors that synthesizes peer-reviewed medical evidence at the point of care
Healthcare📍 Miami, FLFounded 2021
Current Valuation
$12B
as of 2026-Q1
DECACORN
OpenEvidence is a Miami-based clinical AI company often called the 'ChatGPT for doctors' — its copilot synthesizes peer-reviewed medical literature into instantaneous, citation-backed answers at the point of care. Founded in 2021 by Kensho founder Daniel Nadler, it closed a $250M Series D in January 2026 co-led by Thrive Capital and DST Global at a $12B valuation, doubling from $6B six months earlier. Sacra estimates 2025 revenue at $150M, up over 1,800% YoY, with widespread adoption among U.S. physicians.
Company Profile
CEO
Daniel Nadler
Founded
2021
HQ
Miami, FL
Employees
~80
Total Raised
$700M
Est. Revenue
$150M (2025)
Growth
+1,803% YoY revenue growth (Sacra)
Last Round
Series D — $250M (Jan 2026) · Lead: Thrive Capital / DST Global (co-led)
IPO Status
private
Fundraising Status
Series D · $250M · 7 mo ago
privateTotal raised $700M
Secondary Market
Implied price / share
$454.21
Last round price / share
$487.38
vs last round
-6.8%
Open interest
14
Last round price vs secondary price
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series D
$250M
Jan 2026
Thrive Capital / DST Global (co-led)
—
Founders & Key People
Daniel NadlerZachary Ziegler
Investors
Thrive Capital · DST Global · Sequoia Capital · Kleiner Perkins · Coatue · Google Ventures
Products
OpenEvidence Clinical AI Copilot
Point-of-Care Evidence Search
Specialty-Specific Knowledge Graphs
EHR-Integrated Decision Support
Competitors
UpToDate (Wolters Kluwer) · DynaMed · Hippocratic AI · Abridge · Glass Health
AIHealthcareClinical Decision SupportDecacornMedical AI
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2026-Q1. Refreshed quarterly.